Quarterly reports of Rightcrowd, IntelliHR and Volpara update us on free cash flow and annualised recurring revenue growth…

Raiz Invest (ASX: RZI) and Datadot (ASX: DDT) are both relatively out of favour, but both remain operating cashflow positive.

Eroad (ASX: ERD) had a decent quarter but continues to blame the pandemic for tough operating conditions, undermining confidence in management.

By my reckoning this company is trading on about 15 times earnings and yielding at least 4% in dividends. And growth is likely, albeit not certain.

The Genetic Signatures (ASX:GSS) share price has dropped almost 10% despite reporting record receipts from customers.

Even though growth stocks are down considerably, in my view the top quality growth stocks are still up pretty overvalued.

The BeforePay share price is at 29% below the IPO price, but what does BeforePay the company actually do?

DGL Group (ASX:DGL) looks too optimistically priced at a glance, but there are a few features of the company that make me think it could well be one to watch.

I think the Australian Clinical Labs (ASX: ACL) is likely to fall in the short term as the Morrison government moves to restrict PCR testing.

The Ebos Group (ASX: EBO) retail equity offer has me considering if I want to increase my position, or arbitrage the discount for a profit.

This ASX listed med-tech company has an enterprise value of less than $200m, but has expanded its customer base significantly, as a result of the pandemic.

Australian Clinical Labs (ASX:ACL) makes millions in profits from covid testing, and the Omicron variant has seen covid testing increase once more…

The PTB Group (ASX:PTB) share price has recovered strongly from the pandemic, but its growth plans are far from over.

Alcidion (ASX:ALC) is bolstering its product offering with its acquisition of Silverlink Software. What does it mean for shareholders?

PWR Holdings (ASX: PWH) has a valuable brand and claims strong growth prospects…

The new Omicron variant is not causing me to panic, but I am tweaking my portfolio a little to prepare for (likely) harder times ahead.

A confluence of factors make Nearmap well worth watching.

Building a brand new portfolio offers a tantalising fresh start right at a time when stocks are looking wobbly. Here’s the plan…

The Alcidion share price is up around 10% after it confirmed its largest ever contract win, worth at least $23 million.

Claude Walker, Matt Joass, Andrew Page, and Kevin Fung discuss Nanosonics stock and the impact of omicron on investors.